EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

SOCS1 Mimetic Peptide Enhances Empagliflozin Improvement on Kidney Damage in the Type 2 Diabetes Mouse Model BTBR ob/ob

Marcelo Aguilar-Cartes, Lucas Opazo-Ríos iD, Alejandra Droguett, Sebastian Mas-Fontao, Juan Antonio Moreno iD, Carmen Gómez-Guerrero iD, Jesús Egido iD, Sergio Mezzano

International Journal of Molecular Sciences · 08.03.2026 · 27 (5) · 2466

DOI: 10.3390/ijms27052466 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 08.03.2026. Verfasst von Marcelo Aguilar-Cartes und 7 weiteren Autor:innen. Beteiligte Einrichtung: Laboratorio de Nefrología, Facultad de Medicina, Universidad Austral de Chile, Valdivia 5110566, Chile. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Glucosides, Diabetic Nephropathies, Suppressor of Cytokine Signaling 1 Protein. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MICIU/AEI/10.13039/501100011033 and "ERDF/EU", Instituto de Salud Carlos III and Co-funded by the European Union..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diabetic nephropathy (DN) is the leading cause of end-stage renal disease worldwide. During the last few years, remarkable advances have been made in the treatment of DN. Sodium–glucose cotransporter type 2 inhibitors (SGLT2i) consistently prevent or delay albuminuria and renal failure in patients with DN. Prior research from our group highlights the Janus kinase/signal transducers and activators of transcription axis as a critical target in DN. Specifically, the administration of suppression of cytokine signaling 1 (SOCS1) mimetic peptides (MiS1) modulates aberrant signaling, resulting in profound beneficial effects on renal function and structural integrity in experimental DN. The aim of this study was to evaluate the effect of empagliflozin and MiS1 on kidney damage and its associated inflammatory, oxidative stress and lipotoxic mechanisms in an advanced type 2 DN mouse model BTBR ob/ob. Mice were treated for 7 weeks with empagliflozin and MiS1, alone or in combination, and monitored for glycemia, body weight, albuminuria, histopathological damage, podocyte loss, and gene expression related to inflammation, redox balance, and lipid metabolism. Empagliflozin or MiS1 monotherapies significantly reduced albuminuria and structural renal injury, preserved podocyte number, and downregulated genes involved in inflammatory, oxidative, and mitochondrial–lipid metabolic dysregulation, with empagliflozin additionally improving metabolic parameters. Notably, the combined therapy achieved the greatest reduction in albuminuria and histological damage with enhanced suppression of pathogenic inflammatory and metabolic pathways, resulting in superior renoprotection compared with monotherapy. These findings suggested that add-on therapy with SOCS1 peptidomimetics and SGLT2i may help mitigate residual albuminuria and renal damage in type 2 DN.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Benzhydryl CompoundsGlucosidesDiabetic NephropathiesSuppressor of Cytokine Signaling 1 ProteinDiabetes Mellitus, Type 2PeptidesDiabetes Mellitus, ExperimentalAnimalsMiceDisease Models, AnimalOxidative StressKidneyMaleSodium-Glucose Transporter 2 InhibitorsAlbuminuriaPodocytes

Stichwörter der Autor:innen

BTBR ob/obJAK/STAT pathwaySGLT2idiabetic nephropathymeta-inflammation

Substanzen

empagliflozinBenzhydryl CompoundsGlucosidesSuppressor of Cytokine Signaling 1 ProteinSocs1 protein, mouseSodium-Glucose Transporter 2 InhibitorsPeptides

Autor:innen und Institutionen

  • Laboratorio de Nefrología, Facultad de Medicina, Universidad Austral de Chile, Valdivia 5110566, Chile.
  • Facultad de Ciencias de la Salud, Universidad de Las Américas, Concepción-Talcahuano 4301099, Chile.
  • Facultad de Salud, Universidad Santo Tomás, Valdivia 5090000, Chile.
  • Renal, Vascular and Diabetes Research Lab, IIS-Fundación Jiménez Díaz-Universidad Autónoma Madrid, CIBER on Diabetes and Associated Metabolic Diseases (CIBERDEM), 28040 Madrid, Spain.
  • Facultad de Ciencias Biomédicas y de la Salud, Universidad Alfonso X (UAX), Villanueva de la Cañada, 28691 Madrid, Spain.
  • Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Hospital Universitario Reina Sofia, 14004 Córdoba, Spain.

ORCID-Profile: Lucas Opazo-Ríos, Juan Antonio Moreno, Carmen Gómez-Guerrero, Jesús Egido

Förderung

  • MICIU/AEI/10.13039/501100011033 and "ERDF/EU"
  • Instituto de Salud Carlos III and Co-funded by the European Union.

Zitieren

APA

Aguilar-Cartes, M., Opazo-Ríos, L., Droguett, A., Mas-Fontao, S., Moreno, J. A., Gómez-Guerrero, C., Egido, J., & Mezzano, S. (2026). SOCS1 Mimetic Peptide Enhances Empagliflozin Improvement on Kidney Damage in the Type 2 Diabetes Mouse Model BTBR ob/ob. International Journal of Molecular Sciences, 27(5), 2466. https://doi.org/10.3390/ijms27052466

Vancouver

Aguilar-Cartes M, Opazo-Ríos L, Droguett A, Mas-Fontao S, Moreno JA, Gómez-Guerrero C, et al. SOCS1 Mimetic Peptide Enhances Empagliflozin Improvement on Kidney Damage in the Type 2 Diabetes Mouse Model BTBR ob/ob. International Journal of Molecular Sciences. 2026;27(5):2466. doi:10.3390/ijms27052466

BibTeX
@article{AguilarCartes2026,
  author = {Aguilar-Cartes, Marcelo and Opazo-Ríos, Lucas and Droguett, Alejandra and Mas-Fontao, Sebastian and Moreno, Juan Antonio and Gómez-Guerrero, Carmen and Egido, Jesús and Mezzano, Sergio},
  title = {SOCS1 Mimetic Peptide Enhances Empagliflozin Improvement on Kidney Damage in the Type 2 Diabetes Mouse Model BTBR ob/ob},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {5},
  pages = {2466},
  doi = {10.3390/ijms27052466}
}
Kostenlos starten →